An NCI-designated Comprehensive Cancer Center

Alex Herrera, M.D.

Hematologist - Oncologist
Clinical Expertise
Research Focus
  • Immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation

Clinical Teams

Alex Herrera, M.D., earned his undergraduate degree summa cum laude from Princeton University and received his medical degree from Harvard Medical School in Boston. While in Boston, Dr. Herrera completed his residency in internal medicine at the Brigham and Women’s Hospital, before pursuing a hematology-oncology fellowship at the Dana-Farber Cancer Institute/Massachusetts General Hospital. Dr. Herrera is the Leukemia & Lymphoma Society Scholar in Clinical Research. 

Dr. Herrera's clinical and research interests center on immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma. He leads several clinical trials evaluating immune checkpoint inhibitors and other novel agents for the treatment of relapsed or refractory non-Hodgkin lymphoma or classical Hodgkin lymphoma and in lymphoma patients undergoing hematopoietic stem cell transplantation. He also studies biomarkers of response and outcome in patients with lymphoma treated with immunotherapies or hematopoietic stem cell transplantation, including immunohistochemical and cytogenetic biomarkers and sequencing-based circulating tumor DNA detection, as well as gene expression, mutational profiling, and quantitative spatial immunofluorescence of tumor cells and the tumor microenvironment to identify biomarkers predictive of response to a treatment. The goal of these studies is to identify target populations for enrollment in rational prospective clinical trials using biomarker-based interventions to improve outcomes.

Dr. Herrera is the recipient of several honors, grants and awards, including the Leukemia & Lymphoma Society Scholar in Clinical Research Award, American Society of Blood and Marrow Transplantation/Biology of Blood and Marrow Transplantation George Santos Award for Best Clinical Science Article by a New Investigator, American Society of Clinical Oncology/Conquer Cancer Foundation Young Investigator Award, City of Hope K12 Paul Calabresi Career Development Award for Clinical Oncology, and the Lymphoma Research Foundation Larry and Denise Mason Clinical Investigator Career Development Award. He has published over 40 articles in peer-reviewed publications, abstracts and book chapters, and has been invited to present his work nationally and internationally.

Dr. Herrera is a member of the Toni Stephenson Lymphoma Center.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Chen YB, Armand P, Shadman M. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma. Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30513-0. doi: 10.1016/j.bbmt.2019.07.041. [Epub ahead of print]. PMID: 31394277
  • Herrera AF. Noncellular Immune Therapies for Non-Hodgkin Lymphoma. Hematol Oncol Clin North Am. 2019 Aug;33(4):707-725. doi: 10.1016/j.hoc.2019.03.007. Epub 2019 May 11. Review. PMID: 31229164
  • Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Lower GVHD and relapse risk in PTCy-based Haploidentical vs Matched Sibling Donor RIC Transplant for Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2019 May 24. pii: S1083-8791(19)30336-2. doi: 10.1016/j.bbmt.2019.05.025. [Epub ahead of print] PMID: 31132455
  • Moskowitz AJ, Herrera AF, Beaven AW. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy. Am Soc Clin Oncol Educ Book. 2019 Jan;39:477-486. doi: 10.1200/EDBK_238799. Epub 2019 May 17. PMID: 31099645
  • Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol. 2019 May 1. doi: 10.1111/bjh.15923. [Epub ahead of print]. PMID: 31044423
  • Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood. 2019 Apr 5. pii: blood.2019000215. doi: 10.1182/blood.2019000215. [Epub ahead of print]. PMID: 30952672
  • Song JY, Herrera AF. CAR T cells mimicking an aggressive lymphoma. Blood. 2019 Mar 28;133(13):1517. doi: 10.1182/blood-2019-01-896753. PMID: 30923108
  • Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbre C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, Hamadani M. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019 Feb 28. doi: 10.1001/jamaoncol.2018.6278. [Epub ahead of print] PMID: 30816957
  • Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, Boumendil A, Gopal A, Herrera AF, Schmid C, Diez-Martin JL, Fuchs E, Bolaños-Meade J, Gooptu M, Al Malki MM, Castagna L, Ciurea SO, Dominietto A, Blaise D, Ciceri F, Tischer J, Corradini P, Montoto S, Robinson S, Gülbas Z, Hamadani M. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019 Feb 12;3(3):360-369. doi: 10.1182/bloodadvances.2018027748. PMID: 30723110
  • Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 Jan 10;12(1):6. doi: 10.1186/s13045-018-0696-z. PMID: 30630534
  • Herrera AF. Where does PD-1 blockade fit in HL therapy? Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):213-220. doi: 10.1182/asheducation-2018.1.213. Review. PMID: 30504313
  • Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term Safety and Efficacy of Axicabtagene Ciloleucel (Anti-CD19 CAR T) in Refractory Large B-Cell Lymphoma. Lancet Oncol. 2018 Nov 30. pii: S1470-2045(18)30864-7. doi: 10.1016/S1470-2045(18)30864-7. [Epub ahead of print] PMID: 30518502
  • Salhotra A, Mei M, Stiller T, Mokhtari S, Herrera AF, Chen R, Popplewell L, Zain J, Ali H, Sandhu K, Budde E, Nademanee A, Forman SJ, Nakamura R. Outcomes of patients with recurrent and refractory lymphoma undergoing allogeneic hematopoietic cell transplantation with BEAM conditioning and sirolimus and tacrolimus based GVHD prophylaxis. Biol Blood Marrow Transplant. 2018 Sep 15. pii: S1083-8791(18)30566-4. doi: 10.1016/j.bbmt.2018.09.009. [Epub ahead of print] PMID: 30227232
  • Tomassetti S, Herrera AF. Update on the role of brentuximab vedotin in classical Hodgkin lymphoma. Ther Adv Hematol. 2018 Jul 12;9(9):261-272. doi: 10.1177/2040620718786833. eCollection 2018 Sep. PMID: 30210755
  • Darrah JM, Herrera AF. Updates on Circulating Tumor DNA Assessment in Lymphoma. Curr Hematol Malig Rep. 2018 Aug 23. doi: 10.1007/s11899-018-0468-4. [Epub ahead of print] Review. PMID: 30136210
  • Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3. PMID: 29954415
  • Herrera AF, Molina A. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies. Clin Lymphoma Myeloma Leuk. 2018 May 10. pii: S2152-2650(18)30091-0. doi: 10.1016/j.clml.2018.05.006. [Epub ahead of print] Review. PMID: 29804872
  • Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 Apr 24;2(8):933-940. doi: 10.1182/bloodadvances.2018018531. PMID: 29685953
  • Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH. Interim Results of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 2017 Dec 11. PMID: 29229594
  • Herrera AF, Palmer JM, Martin P, Armenian S, Tsai N, Mott M, Sahebi F, Cai J, Siddiqi T, Popplewell L, Nademanee A, Rosen ST, Kwak LW, Forman SJ, Chen R. Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma. Ann Oncol. 2018 Mar 1;29(3):724-730. doi: 10.1093/annonc/mdx791. PMID: 29272364
  • Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P. Outcomes After Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28. PMID: 29196080
  • Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol. 2017 Oct;8(10):293-302. doi: 10.1177/2040620717728000. Epub 2017 Aug 29.  PMID: 29051800
  • Herrera AF and Armand P. Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. J Clin Oncol. 2017 Dec 1;35(34):3877-3887. doi: 10.1200/JCO.2017.74.5281. PMID: 28933999
  • Mei MG, Cao TM, Chen L, Song J, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant. 2017 Nov;23(11):1861-1869. PMID: 28733266
  • *Herrera AF, *Mei M, Low L, Griffin GK, Merryman RW, Song JY, Bedell V, Sun H, Paris T, Stiller T, Brown JR, Budde E, Chan WC, Chen R, Davids MS, Freedman A, Fisher DC, Jacobsen ED, Jacobson CA, Kim HT, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer, J, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, ^Krishnan A, ^Armand P. Double Expressing and Double-Hit Relapsed or Refractory Diffuse Large B-cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. J Clin Oncol. 2017 Jan;35(1):24-31. doi:10.1200/JCO.2016.68.2740. PMID: 28034071 *^These authors contributed equally
  • Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani A, Alyea EP, Carlton VE, Chen YB, Cutler CS, Ho VT, Koreth J, Kotwaliwale C, Nikiforow S, Ritz J, Rodig SJ, Soiffer RJ, Antin JH, Armand P.  Next-Generation Sequencing-Based Detection of Circulating Tumor DNA After Allogeneic Hematopoietic Stem Cell Transplantation for Lymphoma. Br J Haematol. 2016 Oct 6. doi: 10.1111/bjh.14311. PMID: 27711974.
  • Song JY, Song L, Herrera AF, Venkataraman G, Murata-Collins JL, Bedell VH, Chen YY, Kim YS, Tadros R, Nathwani BN, Weisenburger DD, Feldman AL. Cyclin D1 expression in peripheral T-cell lymphomas. Mod Pathol. 2016 Nov;29(11):1306-1312. doi: 10.1038/modpathol.2016.136. PMID: 27469326
  • Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016 Sep 10;34(26):3141-9. doi: 10.1200/JCO.2015.66.3476.PMID: 27269951
  • Herrera AF. Double-Hit Lymphoma: Practicing in a Data-Limited Setting. J Oncol Pract. 2016 Mar;12(3):239-40. PMID: 26962167
  • Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, Devine SM, Waller EK, Jagirdar N, Herrera AF, Cutler C, Ho VT, Koreth J, Alyea EP, McAfee SL, Soiffer RJ, Chen YB, Antin JH. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016 Apr;173(1):96-104. doi: 10.1111/bjh.13931 PMID: 26729448
  • Song JY, Venkataraman G, Fedoriw Y, Herrera AF, Siddiqi T, Alikhan MB, Kim YS, Murata-Collins J, Weisenburger DD, Liu X, Duffield AS. Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults. Leuk Lymphoma. 2016 Apr;57(4):866-71. doi: 10.3109/10428194.2015.1085529. PMID: 26450341
  • Herrera AF, Jacobsen EJ. Ibrutinib in the Treatment of Mantle Cell Lymphoma. Clin Cancer Res. 2014 Nov 1;20(21):5365-71 PMID: 25361916
  • Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP, Armand P, Cutler CS, Ho VT, Nikiforow S, Ritz J, Blazar BR, Antin JH, Soiffer RJ, Koreth J. A Phase II Study Of Proteasome-Inhibition For Initial Therapy Of Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant. 2014 Jul 10. PMID: 25017765
  • Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson M, Nademanee A, Niland J, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS. Comparison of Referring and Final Pathology for Patients with T-Cell Lymphoma in the National Comprehensive Cancer Network. Cancer. 2014 Jul 1;120(13):1993-9. PMID: 24706502
  • Bhatt AS, Freeman SS, Herrera AF, Pedamallu CS, Gevers D, Duke F, Jung J, Michaud M, Walker BJ, Young S, Earl AM, Kostic AD, Ojesina AI, Hasserjian R, Ballen KK, Chen YB, Hobbs G, Antin JH, Soiffer RJ, Baden LR, Garrett WS, Hornick JL, Marty FM, Meyerson M. Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 Aug 8;369(6):517-28. PMID:23924002
  • *Herrera AF, *Soriano G, Bellizi A, Hornick JL, Ho VT, Ballen KK, Baden LR, Cutler CS, Antin JH, Soiffer RJ, Marty FM. Cord Colitis Syndrome In Cord-Blood Stem-Cell Transplantation. N Engl J Med. 2011 Sep 1;365(9):815-24. PMID:21879899  *These authors contributed equally
  • Schreiber YS, Herrera AF, Wilson D, Wallengren K, Draper R, Muller J, Dawood H, Doucette S, Cameron DW, Alvarez GG. Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area. Int J Tuberc Lung Dis. 2009 Oct;13(10):1274-80. PMID:19793433
  • Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. Magnetic Resonance Imaging Captures the Biology of Ductal Carcinoma In Situ, J Clin Oncol. 2006 Oct 1;24(28):4603-10. PMID:17008702
In The News
An Expert's Voice
T cell therapy

New Immunotherapy Research Presented at ASH

breakthroughs - t cells

New Immunotherapy Research Presented at ASH Annual Meeting 2019

T cell therapy

New immunotherapies detailed at ASH conference